Liste des médicaments et vaccins
| DESIGNATION | DCI | TITULAIRE AMM | PAYS D'ORIGINE | PGHT(FCFA) | N°AMM | DATE EXPIRATION AMM |
|---|---|---|---|---|---|---|
| DOLUTEGRAVIR 50mg Comprimé pelliculé B/30 | DOLUTEGRAVIR | LAURUS LABS LIMITED | Inde | 6559.57 | AMM_2024_17226 | 2030-06-30 |
| DOLUTEGRAVIR 50mg Comprimé pelliculé B/90 | DOLUTEGRAVIR | STRIDES PHARMA SCIENCE LTD.. | Inde | 9839.36 | AMM_2020_8380 | 2026-10-31 |
| DOLUTEGRAVIR/LAMIVUDINE/FUMARATE DE TENOFOVIR DISOPROXIL 50mg+300mg+300mg Comprimé pelliculé B/180 | DOLUTEGRAVIR + LAMIVUDINE + FUMARATE DE TENOFOVIR DISOPROXIL | LAURUS LABS LIMITED | Inde | 32797.85 | AMM_2024_17314 | 2030-05-31 |
| DOLUTEGRAVIR/LAMIVUDINE/FUMARATE DE TENOFOVIR DISOPROXIL 50mg+300mg+300mg Comprimé pelliculé B/30 | DOLUTEGRAVIR + LAMIVUDINE + FUMARATE DE TENOFOVIR DISOPROXIL | LAURUS LABS LIMITED | Inde | 13119.14 | AMM_2024_17312 | 2030-05-31 |
| DOLUTEGRAVIR/LAMIVUDINE/FUMARATE DE TENOFOVIR DISOPROXIL 50mg+300mg+300mg Comprimé pelliculé B/90 | DOLUTEGRAVIR + LAMIVUDINE + FUMARATE DE TENOFOVIR DISOPROXIL | LAURUS LABS LIMITED | Inde | 22958.49 | AMM_2024_17313 | 2030-05-31 |
| DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR 50mg+300mg+300mg Comprimé pelliculé B/90 | DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR | SUN PHARMACEUTICALS INDUSTRIES LIMITED | Inde | 16398.93 | AMM_2021_11448 | 2027-07-31 |
| DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR 50mg+300mg+300mg Comprimé B/30 | DOLUTEGRAVIR + LAMIVUDINE + TENOFOVIR | HETERO LABS LTD | Inde | 11807.23 | AMM_2018_4008 | 2023-08-27 |
| DOLVEN 100mg/5mL Suspension buvable Fl/120 mL | IBUPROFENE | TERIAK S.A | Tunisie | 787.15 | AMM_2019_5360 | 2025-07-07 |